-
Roth Capital Positive on Curis (CRIS) Following Q3 Results from Roche/Erivedge
-
Pre-Open Stock Movers 8/25: (ITMN) (THI) (BKW) (LTM) Higher; (RGDO) (QIHU) (THOR) Lower (more...)
-
Roth Cuts PT on Curis (CRIS) to $9; Erivedge Phase 2 Misses Roche's (RHHBY) Internal Expectations
-
Roth Reaffirms Curis (CRIS) at Buy; Erivedge, Internal Pipeline Both Ongoing Strengths